A new trading day began on Monday, with 4D Molecular Therapeutics Inc (NASDAQ: FDMT) stock price down -2.18% from the previous day of trading, before settling in for the closing price of $7.79. FDMT’s price has ranged from $7.32 to $36.25 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 111.29% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged -13.07%. With a float of $39.01 million, this company’s outstanding shares have now reached $43.08 million.
In an organization with 147 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -43747.06%, operating margin of -990447.06%, and the pretax margin is -844000.0%.
4D Molecular Therapeutics Inc (FDMT) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of 4D Molecular Therapeutics Inc is 15.61%, while institutional ownership is 112.66%. The most recent insider transaction that took place on Sep 16 ’24, was worth 8,165. In this transaction Chief Legal Officer of this company sold 500 shares at a rate of $16.33, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Chief Legal Officer sold 500 for $15.00, making the entire transaction worth $7,500. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.77 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.07% per share during the next fiscal year.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Here are 4D Molecular Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 17.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.61 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Let’s dig in a bit further. During the last 5-days, its volume was 0.86 million. That was inferior than the volume of 0.9 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 25.81%. Additionally, its Average True Range was 0.61.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 1.39%, which indicates a significant decrease from 16.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.25% in the past 14 days, which was lower than the 97.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.38, while its 200-day Moving Average is $19.82. However, in the short run, 4D Molecular Therapeutics Inc’s stock first resistance to watch stands at $8.06. Second resistance stands at $8.50. The third major resistance level sits at $8.77. If the price goes on to break the first support level at $7.35, it is likely to go to the next support level at $7.08. The third support level lies at $6.64 if the price breaches the second support level.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
With a market capitalization of 352.26 million, the company has a total of 46,228K Shares Outstanding. Currently, annual sales are 20,720 K while annual income is -100,840 K. The company’s previous quarter sales were 10 K while its latest quarter income was -34,950 K.
